Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Hikma Pharmaceuticals ( (GB:HIK) ) is now available.
Hikma Pharmaceuticals PLC has updated its registered office address to 10 Portman Square, London, W1H 6AZ, effective immediately. The change is primarily administrative in nature, but it formally updates the company’s official corporate domicile details in the U.K., ensuring regulatory and corporate records reflect its current London base.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1870.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a London-headquartered pharmaceutical company operating in the global healthcare industry. The company focuses on developing, manufacturing, and marketing a broad range of branded and generic medicines, supplying hospitals and healthcare providers in multiple international markets.
Average Trading Volume: 1,335,737
Technical Sentiment Signal: Hold
Current Market Cap: £3.05B
For detailed information about HIK stock, go to TipRanks’ Stock Analysis page.